2004

Cellerix was formed within the Genetrix Group.

Cellerix closes a series A financing round worth €1.3 million led by Genetrix and the Management Team.

Cellerix is licensed as a Pharmaceutical Company.

The Phase II clinical trial with Ontaril^® for treatment of complex perianal fistulas starts.

2005

Cellerix closes a serie A financing round worth €4.3 million led by Genetrix and private investors.

Orphan drug designation for Ontaril^® in Europe is granted.

2006

Cellerix closes the first tranche of a series A financing round in November.

The Phase II trial of Ontaril^® (acute phase) is successfully completed.

Cx501 is granted orphan drug status in Europe.

2007

Cellerix closes a series B financing round worth €27.2 million led by Life Science Partners (Netherlands), Ventech (France) and Ysios Asset Management (Spain). International Corporate Venture Funds (Novartis (Switzerland) and Roche (Switzerland)) as well as other financial investors (Genera (Spain) and Biopartners (Spain)), existing shareholders (Genetrix y Nerel) and the Management Team also participated in this round.

Cellerix concludes a licensing agreement with Axcan Pharma Inc. to develop Ontaril^® in North America (Canada, USA and Mexico), an agreement that could be worth as much as US$40 million in the form of an upfront payment and milestone payments

The Phase III clinical trial with Ontaril^® for treating complex perianal fistulas in patients without inflammatory bowel disease starts.

The Phase I/II clinical trial of Cx501 for the treatment of recessive dystrophic epidermolysis bullosa gets underway.